Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Reviews in Clinical and Experimental Pharmacology
  4. Volume 20, Issue 2
  5. Article
Volume 20, Issue 2
  • ISSN: 2772-4328
  • E-ISSN: 2772-4336

Abstract

Large uterine fibroids (UFs) are clonal neoplasms of the uterus that form during the mid and late-aged women. Such women generally consume oral contraceptive pills, tranexamic acid, or NSAIDS to manage heavy menstrual bleeding (HMB) and associated complications while waiting for a conclusive procedure or avoiding hysterectomy. The procoagulant effect of these medicinal agents can result in venous stasis of the lower limbs, leading to deep vein thrombosis (DVT), a challenging complication with HMB. We examine the complicated state of heavy bleeding with thrombosis and explore better management options. It has been seen that women with hypothyroidism have an increased risk of getting DVT due to an alteration in the coagulation system. These incidences are mostly associated with higher uterine weight, which is related to the extrinsic compression of the inferior vena cava. In such cases, the occurrence of postoperative thrombosis is riskier if hysterectomy/myomectomy is the only option. Utilization of appropriate anticoagulants with modification of the steroid-hormone system using hormone agonists or antagonists (., levonorgestrel intrauterine system, high-dose progestin-only therapy, danazol, aromatase inhibitors, Vitamin-D supplements or selective estrogen receptor modulators) could be an effective technique, but adverse consequences of continued use should be monitored. More research is needed into the basic biology associated with the role of growth factors and genetic alterations in these malignancies. The development of new leiomyomas following conservative therapy is also a significant issue.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crcep/10.2174/0127724328317631240925051326
2024-10-09
2025-04-06

  • From This Site

    /content/journals/crcep/10.2174/0127724328317631240925051326
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. OrlandoM.S. SinhaA. YaoM. ShippeyE. KhoR.M. Perioperative venous thromboembolism in patients undergoing hysterectomy for fibroids: A nationwide sample.J. Minim. Invasive Gynecol.20222911S2S310.1016/j.jmig.2022.09.020
     [Google Scholar]
  2. ShafferR.K. FastA.M. VuK.N. DobberfuhlA.D. GhanouniP. ChenB. Association between uterine fibroid findings on pelvic MRI, bleeding symptoms, and quality of life (19Q).Obstet. Gynecol.20181311189S10.1097/01.AOG.0000533231.44638.dd
     [Google Scholar]
  3. KyrleP.A. EichingerS. Deep vein thrombosis.Lancet200536594651163117410.1016/S0140‑6736(05)71880‑8 15794972
     [Google Scholar]
  4. HeitJ.A. O’FallonW.M. PettersonT.M. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: A population-based study.Arch. Intern. Med.2002162111245124810.1001/archinte.162.11.1245 12038942
     [Google Scholar]
  5. AntonA. CampreciósG. Pérez-CampuzanoV. OrtsL. García-PagánJ.C. Hernández-GeaV. The pathophysiology of portal vein thrombosis in cirrhosis: Getting deeper into Virchow’s Triad.J. Clin. Med.202211380010.3390/jcm11030800 35160251
     [Google Scholar]
  6. LatifH. Baez SosaV. FaridS. Venous thromboembolism in women with uterine fibroids.Blood2020136Suppl. 1282910.1182/blood‑2020‑136678
     [Google Scholar]
  7. TinawiM. Massive uterine fibroid resulting in extensive deep venous thrombosis, compartment syndrome and rhabdomyolysis.Arch. Intern. Med. Res.202031697310.26502/aimr.0024
     [Google Scholar]
  8. AnaganiM. AgrawalP. AgrawalR. Acute right lower limb deep venous thrombosis due to pressure from large adenomyotic uterus-laparoscopic management.Int. J. Reprod. Contracept. Obstet. Gynecol.20209114749475310.18203/2320‑1770.ijrcog20204850
     [Google Scholar]
  9. CiebieraM. AliM. ZgliczyńskaM. SkrzypczakM. Al-HendyA. Vitamins and uterine fibroids: Current data on pathophysiology and possible clinical relevance.Int. J. Mol. Sci.20202115552810.3390/ijms21155528 32752274
     [Google Scholar]
  10. CiebieraM. WłodarczykM. ZgliczyńskiS. ŁozińskiT. WalczakK. CzekierdowskiA. The role of miRNA and related pathways in pathophysiology of uterine fibroids—from bench to bedside.Int. J. Mol. Sci.2020218301610.3390/ijms21083016 32344726
     [Google Scholar]
  11. OkonofuaF. Uterine fibroid and hysterectomy. Contemporary obstetrics and gynecology for developing countries.ChamSpringer2021451460
     [Google Scholar]
  12. FangC. YangJ. DingW. Incidence of symptomatic deep vein thrombosis after gynecological surgery: A retrospective study in Chinese population.Eur. J. Gynaecol. Oncol.201940693994210.12892/ejgo4675.2019
     [Google Scholar]
  13. LevinV. BoothR. MinassianS. Bleeding disorders and ART. Textbook of assisted reproduction.Berlin, HeidelbergSpringer Link202010.1007/978‑981‑15‑2377‑9_35
     [Google Scholar]
  14. YuP.T. ChenC.Y. LinC.Y. Uterine Myoma— induced venal thrombosis and acute pulmonary thromboembolism: 2 case reports.Airiti Lib2019343133138
     [Google Scholar]
  15. FinianosE.S. YacoubS.F. ChammasM.F. Ovarian vein thrombosis complicated by pulmonary embolism after cesarean delivery in the presence of a large fibroid: Case report and literature review of contributing factors.Case Rep. Obstet. Gynecol.202120211710.1155/2021/6389713 34540300
     [Google Scholar]
  16. RamziD.W. LeeperK.V. DVT and pulmonary embolism: Part I. Diagnosis.Am. Fam. Physician2004691228292836 15222648
     [Google Scholar]
  17. TinelliA. VinciguerraM. MalvasiA. AndjićM. BabovićI. SparićR. Uterine fibroids and diet.Int. J. Environ. Res. Public Health2021183106610.3390/ijerph18031066 33504114
     [Google Scholar]
  18. DonnezJ. CarmonaF. Maitrot-ManteletL. DolmansM.M. ChapronC. Uterine disorders and iron deficiency anemia.Fertil. Steril.2022118461562410.1016/j.fertnstert.2022.08.011 36182260
     [Google Scholar]
  19. KirschenG.W. AlAshqarA. Miyashita-IshiwataM. ReschkeL. El SabehM. BorahayM.A. Vascular biology of uterine fibroids: Connecting fibroids and vascular disorders.Reproduction20211622R1R1810.1530/REP‑21‑0087 34034234
     [Google Scholar]
  20. DonnezJ. Uterine fibroids and progestogen treatment: Lack of evidence of its efficacy: A review.J. Clin. Med.2020912394810.3390/jcm9123948 33291422
     [Google Scholar]
  21. AboS. SmithD. StadtM. LaytonA. Modelling female physiology from head to Toe: Impact of sex hormones, menstrual cycle, and pregnancy.J. Theor. Biol.202254011107410.1016/j.jtbi.2022.111074 35227731
     [Google Scholar]
  22. YinH. LoJ.H. KimJ.Y. Expression profiling of nuclear receptors identifies key roles of NR4A subfamily in uterine fibroids.Mol. Endocrinol.201327572674010.1210/me.2012‑1305 23550059
     [Google Scholar]
  23. RanhotraH.S. The NR4A orphan nuclear receptors: Mediators in metabolism and diseases.J. Recept. Signal Transduct. Res.201535218418810.3109/10799893.2014.948555 25089663
     [Google Scholar]
  24. StewartE.A. Laughlin-TommasoS.K. CatherinoW.H. LalitkumarS. GuptaD. VollenhovenB. Uterine fibroids.Nat. Rev. Dis. Primers2016211604310.1038/nrdp.2016.43
     [Google Scholar]
  25. ZannottiA. GrecoS. PellegrinoP. Macrophages and immune responses in uterine fibroids.Cells202110598210.3390/cells10050982 33922329
     [Google Scholar]
  26. GaoL. GeL. ZhuM. YaoX. Association between tumor necrosis factor α and uterine fibroids.Medicine (Baltimore)20209933e2166710.1097/MD.0000000000021667 32872031
     [Google Scholar]
  27. HamzaqF.M. Al-HilliN.M. Correlation between serum interleukin-33 level and uterine fibroids. Prof.(Dr).RK Sharma20202044722
     [Google Scholar]
  28. NarzullayevaN.S. Innovative methods of diagnosis and treatment in women with infertility associated with uterine fibroids.J. Pharm. Negat. Results202243313332110.47750/pnr.2022.13.S08.407
     [Google Scholar]
  29. HouA. YanZ. ZhangY. HouJ. Oral administration of mifepristone combined with ultrasound-guided radiofrequency ablation in treating patients with uterine fibroids: Efficacy, safety, and alternations of inflammatory cytokines, adhesion molecules, and growth factors.J. Nanomater.202120211710.1155/2021/9946224
     [Google Scholar]
  30. BaranovV.S. OsinovskayaN.S. YarmolinskayaM.I. Pathogenomics of uterine fibroids development.Int. J. Mol. Sci.20192024615110.3390/ijms20246151 31817606
     [Google Scholar]
  31. De GregorioA. BekesI. De-GregorioN. Comparison of preoperative serum VEGF in leiomyosarcoma and uterus myomatosus patients: A proof of concept study.J. Clin. Oncol.20193715e1711710.1200/JCO.2019.37.15_suppl.e17117
     [Google Scholar]
  32. YangM.J. YuR.Q. ChenW. ChenJ.Y. WangZ.B. A prediction of NPVR≥ 80% of ultrasound-guided high-intensity focused ultrasound ablation for uterine fibroids.Front. Surg.2021866312810.3389/fsurg.2021.663128 34150838
     [Google Scholar]
  33. ZengL. YangK. LiuH. ZhangG. A network pharmacology approach to investigate the pharmacological effects of Guizhi Fuling Wan on uterine fibroids.Exp. Ther. Med.20171454697471010.3892/etm.2017.5170 29201170
     [Google Scholar]
  34. YangQ. Al-HendyA. Update on the role and regulatory mechanism of extracellular matrix in the pathogenesis of uterine fibroids.Int. J. Mol. Sci.2023246577810.3390/ijms24065778 36982852
     [Google Scholar]
  35. AliM. EsfandyariS. Al-HendyA. Evolving role of microRNAs in uterine fibroid pathogenesis: Filling the gap!Fertil. Steril.202011361167116810.1016/j.fertnstert.2020.04.011 32482253
     [Google Scholar]
  36. ChuangT.D. QuintanillaD. BoosD. KhorramO. Long noncoding RNA MIAT modulates the extracellular matrix deposition in leiomyomas by sponging MiR-29 family.Endocrinology202116211bqab18610.1210/endocr/bqab186 34491311
     [Google Scholar]
  37. ChuangT.D. RehanA. KhorramO. Tranilast induces MiR-200c expression through blockade of RelA/p65 activity in leiomyoma smooth muscle cells.Fertil. Steril.202011361308131810.1016/j.fertnstert.2019.12.002 32199621
     [Google Scholar]
  38. BernsteinD.L. JiangX. RomS. let-7 microRNAs: Their role in cerebral and cardiovascular diseases, inflammation, cancer, and their regulation.Biomedicines20219660610.3390/biomedicines9060606 34073513
     [Google Scholar]
  39. LeppertP.C. JayesF.L. SegarsJ.H. The extracellular matrix contributes to mechanotransduction in uterine fibroids.Obstet. Gynecol. Int.2014201411210.1155/2014/783289 25110476
     [Google Scholar]
  40. MoroE. DegliE.E. BorgheseG. The impact of hormonal replacement treatment in postmenopausal women with uterine fibroids: A state-of-the-art review of the literature.Medicina (Kaunas)201955954910.3390/medicina55090549 31480288
     [Google Scholar]
  41. MlodawskaO.W. SainiP. ParkerJ.B. Epigenomic and enhancer dysregulation in uterine leiomyomas.Hum. Reprod. Update202228451854710.1093/humupd/dmac008 35199155
     [Google Scholar]
  42. El AndaloussiA. Al-HendyA. IsmailN. BoyerT.G. HalderS.K. Introduction of somatic mutation in MED12 induces Wnt4/β-catenin and disrupts autophagy in human uterine myometrial cell.Reprod. Sci.202027382383210.1007/s43032‑019‑00084‑7 32046450
     [Google Scholar]
  43. KoltsovaA. EfimovaO. PendinaA. A view on uterine leiomyoma genesis through the prism of genetic, epigenetic and cellular heterogeneity.Int. J. Mol. Sci.2023246575210.3390/ijms24065752 36982825
     [Google Scholar]
  44. DasD. BanerjeeA. JenaA.B. DuttaroyA.K. PathakS. Essentiality, relevance, and efficacy of adjuvant/combinational therapy in the management of thyroid dysfunctions.Biomed. Pharmacother.202214611261310.1016/j.biopha.2022.112613 35062076
     [Google Scholar]
  45. WeiW.T. LiuP.P.S. LinS.M. Hypothyroidism and the risk of venous thromboembolism: A nationwide cohort study.Thromb. Haemost.2020120350551410.1055/s‑0039‑3402761 32028535
     [Google Scholar]
  46. GargD.S.S. RamalakshmiD.S. Menstrual disorders in chronic kidney disease: Causes and management.Int J Clin Obstetrics Gynaecol20204235335810.33545/gynae.2020.v4.i2f.549
     [Google Scholar]
  47. LiS. LiW. ShengB. ZhuX. Relationship between thyroid disorders and uterine fibroids among reproductive-age women.Endocr. J.202168221121910.1507/endocrj.EJ20‑0340 33028746
     [Google Scholar]
  48. YukJ.S. KimJ.M. Uterine fibroids increase the risk of thyroid goiter and thyroid nodules.Sci. Rep.2022121662010.1038/s41598‑022‑10625‑x 35459918
     [Google Scholar]
  49. DolmansM.M. CacciottolaL. DonnezJ. Conservative management of uterine fibroid-related heavy menstrual bleeding and infertility: Time for a deeper mechanistic understanding and an individualized approach.J. Clin. Med.20211019438910.3390/jcm10194389 34640407
     [Google Scholar]
  50. CaytonV.K.C. FacadioA.M. MaherJ.Y. CrossC.I. Fibroids and endometrial receptivity/embryo implantation.Fibroids Reprod202034233210.1201/9780203728987‑3
     [Google Scholar]
  51. LevaiA.M. RotarI.C. MuresanD. Torsion of a uterine leiomyoma – a rare cause of hemoperitoneum; a case report and review of the literature.Med. Ultrason.2019211778210.11152/mu‑1784 30779835
     [Google Scholar]
  52. BrewsterL.M. PerrottaI.D. JagernathZ. TaherzadehZ. van MontfransG.A. Ultrastructural changes in resistance arterioles of normotensive and hypertensive premenopausal women with uterine fibroids.Ultrastruct. Pathol.202347210411510.1080/01913123.2023.2171168 36780499
     [Google Scholar]
  53. ShiotaM. KotaniY. UmemotoM. Deep-vein thrombosis is associated with large uterine fibroids.Tohoku J. Exp. Med.20112242878910.1620/tjem.224.87 21576892
     [Google Scholar]
  54. RaguramanaS. VathananV. Lower extremity deep venous thrombosis and pulmonary embolism associated with an uterine leiomyoma.Sri Lanka J Obstetrics Gynaecol20204213210.4038/sljog.v42i1.7931
     [Google Scholar]
  55. Kościelna-BuczekK. MędońE. WiduchM. KończykB. KuczmikW. UrbanekT. Lumbar overlordosis—towards the better understanding of the May-Thurner syndrome pathogenesis.Chirurgia Polska2021232110
     [Google Scholar]
  56. KhaundA. LumsdenM.A. Impact of fibroids on reproductive function.Best Pract. Res. Clin. Obstet. Gynaecol.200822474976010.1016/j.bpobgyn.2008.01.009 18547868
     [Google Scholar]
  57. PandurevicS. MacutD. FanelliF. PagottoU. GambineriA. Biomediators in polycystic ovary syndrome and cardiovascular risk.Biomolecules2021119135010.3390/biom11091350 34572562
     [Google Scholar]
  58. NavarroA. BarianiM.V. YangQ. Al-HendyA. Understanding the impact of uterine fibroids on human endometrium function.Front. Cell Dev. Biol.2021963318010.3389/fcell.2021.633180 34113609
     [Google Scholar]
  59. AliM. ChaudhryZ.T. Al-HendyA. Successes and failures of uterine leiomyoma drug discovery.Expert Opin. Drug Discov.201813216917710.1080/17460441.2018.1417381 29254389
     [Google Scholar]
  60. MoulderJ.K. SiedhoffM.T. TillS.R. MollS. Management considerations for patients with uterine fibroids and concurrent venous thromboembolism.Curr. Opin. Obstet. Gynecol.201628432933510.1097/GCO.0000000000000286 27253238
     [Google Scholar]
  61. SerfatyD. Update on the contraceptive contraindications.J. Gynecol. Obstet. Hum. Reprod.201948529730710.1016/j.jogoh.2019.02.006 30796985
     [Google Scholar]
  62. JamesP.D. Women and bleeding disorders: Diagnostic challenges.Hematology (Am. Soc. Hematol. Educ. Program)20202020154755210.1182/hematology.2020000140
     [Google Scholar]
  63. ParazziniF. ChiaffarinoF. PolverinoG. ChianteraV. SuraceM. La VecchiaC. Uterine fibroids risk and history of selected medical conditions linked with female hormones.Eur. J. Epidemiol.200319324925310.1023/B:EJEP.0000020448.43323.2a 15117118
     [Google Scholar]
  64. KeenanL. KerrT. DuaneM. Van GundyK. Systematic review of hormonal contraception and risk of venous thrombosis.Linacre Q.201885447047710.1177/0024363918816683 32431379
     [Google Scholar]
  65. GoldhaberS.Z. Risk factors for venous thromboembolism.J. Am. Coll. Cardiol.20105611710.1016/j.jacc.2010.01.057 20620709
     [Google Scholar]
  66. PickarJ.H. MacNeilT. OhlethK. SERMs: Progress and future perspectives.Maturitas201067212913810.1016/j.maturitas.2010.05.009 20580502
     [Google Scholar]
  67. PillaiL.S. RegidiS. VargheseS.D. Nonhormonal selective estrogen receptor modulator 1‐(2‐(4‐{(3R, 4S)‐7‐Methoxy‐2, 2‐dimethyl‐3‐phenyl‐chroman‐4yl} phenoxy) ethyl) pyrrolidine hydrochloride (ormeloxifene hydrochloride) for the treatment of breast cancer.Drug Dev. Res.201879627528610.1002/ddr.21440 30284735
     [Google Scholar]
  68. McCormackP.L. Tranexamic Acid.Drugs201272558561710.2165/11209070‑000000000‑00000 22397329
     [Google Scholar]
  69. BerntorpE. FollrudC. LethagenS. No increased risk of venous thrombosis in women taking tranexamic acid.Thromb. Haemost.2001862714715 11522029
     [Google Scholar]
  70. BofillR.M. LethabyA. FarquharC. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding.Cochrane Libr.201920199CD00040010.1002/14651858.CD000400.pub4 31535715
     [Google Scholar]
  71. BalkanskyS. PeikovaL. GrigorovE. GetovI. A review of the use of low-dose acetylsalicylic acid for antithrombotic therapy. S’rdechno-s’ dovi Zabolyavaniya/Medical Review-.Cardiovasc. Dis.201445339
     [Google Scholar]
  72. EvansJ. SalamonsenL.A. Inflammation, leukocytes and menstruation.Rev. Endocr. Metab. Disord.201213427728810.1007/s11154‑012‑9223‑7 22865231
     [Google Scholar]
  73. MaybinJ.A. CritchleyH.O.D. Medical management of heavy menstrual bleeding.Womens Health (Lond. Engl.)2016121273410.2217/whe.15.100 26695687
     [Google Scholar]
  74. De La CruzM.S.D. BuchananE.M. Uterine fibroids: Diagnosis and treatment.Am. Fam. Physician2017952100107 28084714
     [Google Scholar]
  75. DiVastaA.D. LauferM.R. GordonC.M. Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis.J. Pediatr. Adolesc. Gynecol.200720529329710.1016/j.jpag.2007.04.008 17868896
     [Google Scholar]
  76. KavoussiS.K. EsquedaA.S. JukesL.M. Elagolix to medically treat a uterine adenomyoma: A case report.Eur. J. Obstet. Gynecol. Reprod. Biol.202024726626710.1016/j.ejogrb.2020.02.027 32088070
     [Google Scholar]
  77. DonnezO. DonnezJ. Gonadotropin-releasing hormone antagonist (linzagolix): A new therapy for uterine adenomyosis.Fertil. Steril.2020114364064510.1016/j.fertnstert.2020.04.017 32507315
     [Google Scholar]
  78. SyedY.Y. Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A review in symptomatic uterine fibroids.Drugs2022618
     [Google Scholar]
  79. DonnezJ. Liver injury and ulipristal acetate: An overstated tragedy?Fertil. Steril.2018110459359510.1016/j.fertnstert.2018.06.044 30196943
     [Google Scholar]
  80. AngioniS. D’AlterioM.N. DaniilidisA. Highlights on medical treatment of uterine fibroids.Curr. Pharm. Des.202127363821383210.2174/18734286MTEysOTUkw 33388011
     [Google Scholar]
  81. CiebieraM. VitaleS.G. FerreroS. Vilaprisan, a new selective progesterone receptor modulator in uterine fibroid pharmacotherapy-will it really be a breakthrough?Curr. Pharm. Des.202026330030910.2174/1381612826666200127092208 31985366
     [Google Scholar]
  82. BhatnagarA.S. BrodieA.M.H. LongB.J. EvansD.B. MillerW.R. Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors.J. Steroid Biochem. Mol. Biol.2001761-519920210.1016/S0960‑0760(01)00050‑4 11384878
     [Google Scholar]
  83. MoroniR.M. FerrianiR.A. Candido-dos-ReisF.J. BritoL.G.O. VieiraC.S. Pharmacological treatment of uterine fibroids.Ann. Med. Health Sci. Res.201449Suppl. 318510.4103/2141‑9248.141955 25364587
     [Google Scholar]
  84. VedanthamS. GoldhaberS.Z. JulianJ.A. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis.N. Engl. J. Med.2017377232240225210.1056/NEJMoa1615066 29211671
     [Google Scholar]
  85. BarnabyJ. MartynovA. ShahS. RamanathanA. Giant subserosal myoma causing deep venous thrombosis in a patient with pre-existing May-Thurner syndrome.Radiol. Case Rep.202015664464910.1016/j.radcr.2020.02.010 32280393
     [Google Scholar]
  86. ChanN. Sobieraj-TeagueM. EikelboomJ.W. Direct oral anticoagulants: Evidence and unresolved issues.Lancet2020396102641767177610.1016/S0140‑6736(20)32439‑9 33248499
     [Google Scholar]
  87. SchwarbH. TsakirisD. New direct oral anticoagulants (DOAC) and their use today.Dent. J.201641510.3390/dj4010005 29563447
     [Google Scholar]
  88. MüllerM. EastlineJ. NaglerM. ExadaktylosA.K. SauterT.C. Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: Indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists.Scand. J. Trauma Resusc. Emerg. Med.20192714810.1186/s13049‑019‑0625‑3 31014373
     [Google Scholar]
  89. WhiteK. FaruqiU. CohenA.A.T. New agents for DOAC reversal: A practical management review.Br. J. Cardiol.20222911 35747314
     [Google Scholar]
  90. BinyminK.A. NasherM. PatelD. Warfarin-induced deep vein thrombosis.Int. Med. Case Rep. J.2014712312510.2147/IMCRJ.S62100 25246809
     [Google Scholar]
  91. VranckxP. ValgimigliM. HeidbuchelH. The Significance of drug—Drug and drug—Food interactions of oral anticoagulation.Arrhythm. Electrophysiol. Rev.201871556110.15420/aer.2017.50.1 29636974
     [Google Scholar]
  92. ArepallyG.M. Heparin-induced thrombocytopenia.Blood2017129212864287210.1182/blood‑2016‑11‑709873 28416511
     [Google Scholar]
  93. IekoM. TarumiT. NakabayashiT. YoshidaM. NaitoS. KoikeT. Factor Xa inhibitors: New anti-thrombotic agents and their characteristics.Front. Biosci.200611123224810.2741/1794 16146728
     [Google Scholar]
  94. ArbitB. NishimuraM. HsuJ.C. Reversal agents for direct oral anticoagulants: A focused review.Int. J. Cardiol.201622324425010.1016/j.ijcard.2016.07.304 27541665
     [Google Scholar]
  95. Van GorpR. SchurgersL. New insights into the pros and cons of the clinical use of vitamin K antagonists (VKAs) versus direct oral anticoagulants (DOACs).Nutrients20157119538955710.3390/nu7115479 26593943
     [Google Scholar]
  96. GoldhaberS.Z. ErikssonH. KakkarA. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER ®, RE-COVER™ II, and RE-MEDY™.Vasc. Med.201621650651410.1177/1358863X16668588 27807306
     [Google Scholar]
  97. DienerH.C. ConnollyS.J. EzekowitzM.D. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: A subgroup analysis of the RE-LY trial.Lancet Neurol.20109121157116310.1016/S1474‑4422(10)70274‑X 21059484
     [Google Scholar]
  98. CohenA.T. BauersachsR. Rivaroxaban and the EINSTEIN clinical trial programme.Blood Coagul. Fibrinolysis2019303859510.1097/MBC.0000000000000800 30920394
     [Google Scholar]
  99. MoikF. PoschF. ZielinskiC. PabingerI. AyC. Direct oral anticoagulants compared to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis: Updated systematic review and meta‐analysis of randomized controlled trials.Res. Pract. Thromb. Haemost.20204455056110.1002/rth2.12359 32548553
     [Google Scholar]
  100. StefanoV.D. MartinelliI. Rare thromboses of cerebral, splanchnic and upper-extremity veins.Thromb. Haemost.201010361136114410.1160/TH09‑12‑0873 20352171
     [Google Scholar]
  101. MartinelliI. LensingA.W.A. MiddeldorpS. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.Blood2016127111417142510.1182/blood‑2015‑08‑665927 26696010
     [Google Scholar]
  102. CarrierM. Abou-NassarK. MallickR. Apixaban to prevent venous thromboembolism in patients with cancer.N. Engl. J. Med.2019380871171910.1056/NEJMoa1814468 30511879
     [Google Scholar]
  103. RaskobG. AgenoW. CohenA.T. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE study.Lancet Haematol.201635e228e23610.1016/S2352‑3026(16)00023‑5 27132697
     [Google Scholar]
  104. SkjøthF. LarsenT.B. RasmussenL.H. LipG.Y. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.Thromb. Haemost.20141115981988 24577485
     [Google Scholar]
/content/journals/crcep/10.2174/0127724328317631240925051326
Loading
Bleeding vs Thrombosis: Treatment Strategy for Women Having Large Uterine Fibroids and DVT
Curr Rev Clin Exper Pharm 20, 103 (2025); https://doi.org/10.2174/0127724328317631240925051326
/content/journals/crcep/10.2174/0127724328317631240925051326
/content/journals/crcep/10.2174/0127724328317631240925051326
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): anticoagulants; deep venous thrombosis; heavy mensuration bleeding; hypothyroidism; progesterone; Uterine fibroids

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test